Endocrine treatment of male-to-female transsexuals using gonadotropin-releasing hormone agonist

Experimental and Clinical Endocrinology and Diabetes

Volumn 113, Issue 10, 2005, Pages 586-592

  Dittrich, R ^a   Binder, H ^a   Cupisti, S ^a   Hoffmann, I ^a   Beckmann, M W ^a   Mueller, Andreas ^a  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

Author keywords

Cross sex hormone treatment; GnRH analogues; Transsexuals

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ESTRADIOL VALERATE; GONADORELIN AGONIST; GONADOTROPIN; GOSERELIN; LIPID; LIVER ENZYME; PROLACTIN; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE;

ADULT; ARTICLE; BONE DENSITY; BONE MINERAL; BREAST; CONTROLLED STUDY; ESTRADIOL BLOOD LEVEL; FEMINIZATION; FEMUR NECK; GALLSTONE; GENE MUTATION; HOMOZYGOSITY; HORMONAL THERAPY; HUMAN; LUMBAR VERTEBRA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TRANSSEXUALISM; VEIN THROMBOSIS;

ADULT; BONE AND BONES; BONE DENSITY; BREAST; ESTRADIOL; FEMALE; GONADOTROPIN-RELEASING HORMONE; HORMONES; HUMANS; LIPIDS; LIVER; MALE; PITUITARY GLAND; THROMBOEMBOLISM; TRANSSEXUALISM;

EID: 29144497928     PISSN: 09477349     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2005-865900     Document Type: Article

References (41)

1. Adlercreutz H, Tenhunen R. Some aspects of the interaction between natural and synthetic female sex hormones and the liver. Am J Med 1970; 49: 630-648
2. Aedo AR, Landgren BM, Diczfalusy E. Pharmacokinetics and biotransformation of orally administered oestrone sulphate and oestradiol valerate in postmenopausal women. Maturitas 1990; 12: 333-343
3. Aldinger K, Ben Menachem Y, Whalen G. Focal nodular hyperplasia of the liver associated with high-dosage estrogens. Arch Intern Med 1977; 137: 357-359
4. Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H, Bonds D, Brunner R, Brzyski R, Caan B, Chlebowski R, Curb D, Gass M, Hays J, Heiss G, Hendrix S, Howard BV, Hsia J, Hubbell A, Jackson R, Johnson KC, Judd H, Kotchen JM, Kuller L, LaCroix AZ, Lane D, Langer RD, Lasser N, Lewis CE, Manson J, Margolis K, Ockene J, O'Sullivan MJ, Phillips L, Prentice RL, Ritenbaugh C, Robbins J, Rossouw JE, Sarto G, Stefanick ML, Van Horn L, Wactawski-Wende J, Wallace R, Wassertheil-Smoller S, Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. J Am Med Assoc 2004; 291: 1701-1712
5. Asscheman H, Gooren L, Assies J, Smith J, De Siegte R. Prolactin levels and pituitary enlargement in hormone-treated male to female transsexual people. Clin Endocrinol (Oxford) 1988; 28: 583-588
6. Asscheman H, Gooren L, Eklund P. Mortality and morbidity in transsexual patients with cross-gender hormone treatment. Metabolism 1989; 38: 869-873
7. Berrut G, Ghali A, Quere I, Ternisien C, Gallois I, Roy PM, Marre M, Fressinaud P. A common mutation C677T in the 5,10-methyltetrahydrofolate reductase gene is associated to idiopathic deep venous thrombosis. Revue de Médecine Interne 2003; 24: 569-576
8. Cushman M, Kuller LH, Prentice R, Rodabough RJ, Psaty BM, Stafford RS, Sidney S, Rosendaal FR, Women's Health Initiative Investigators. Estrogen plus progestin and risk of venous thrombosis. J Am Med Assoc 2004; 292: 1573-1580
9. den Heijer M. Hyperhomocysteinaemia as a risk factor for venous thrombosis: an update of the current evidence. Clinical Chemistry and Laboratory Medicine CCLM/FESCC 2003; 41: 1404-1407
10. Futterweit W. Endocrine management of transsexual: hormonal profiles of serum prolactin, testosterone, and estradiol. New York State J Medicine 1980; 80: 1260-1264
11. Gooren L, Assies J, Asscheman H, de Slegte R, van Kessel H. Estrogen-induced prolactinoma in a man. J Clin Endocrinol Metab 1988; 66: 444-446
12. Hamburger C. Endocrine treatment of male and female transsexualism. In: Green R, Money J (eds). Transsexualism and Sex Reassignment. Baltimore: Johns Hopkins Press, 1969: 291-307
13. Hannaford P, Croft P, Kay C. Oral contraception and stroke. Stroke 1994; 25: 935-942
14. Harry Benjamin International Gender Dysphoria Association. The Harry Benjamin International Gender Dysphoria Association standards of care for gender identity disorders. 6th version (November 17th, 2001). http://www.hbigda.org/ soc.html. Retrieved 2002
15. Kacar S, Akdogan M, Kosar Y, Parlak E, Sasmaz N, Oguz P, Aydog G. Estrogen and cyproterone acetate combination-induced autoimmune hepatitis. J Clin Gastroenterol 2002; 35: 98-100
16. Khosla S, Melton LJ 3rd, Atkinson EJ, O'Fallon WM, Klee GG, Riggs BL Relationship of serum sex steroid levels and bone turnover markers with bone mineral density in men and women: a key role for bioavailable estrogen. J Clin Endocrinol Metab 1998; 83: 2266-2274
17. Kuhl H. Pharmacology of estradiol and estriol. Menopause Rev 2000; 5: 23-44
18. Levy A, Crown A, Reid R. Endocrine intervention for transsexuals. Clin Endocrinol 2003; 59: 409-418
19. Lin AD, Chen KK, Lin AT, Chang YH, Wu HH, Kuo JY, Huang WJ, Hsu YS, Chung HJ, Chang LS. Antiandrogen-associated hepatotoxicity in the management of advanced prostate cancer. J Chinese Med Assoc 2003; 66: 735-740
20. Meyer WJR, Webb A, Stuart CA, Finkelstein JW, Lawrence B, Walker PA. Physical and hormonal evaluation of transsexual patients: a longitudinal study. Arch Sexual Behavior 1986; 15: 121-138
21. Michel A, Mormont C, Legros J. A psycho-endocrinological overview of transsexualism. Eur J Endocrinol 2001; 145: 365-376
22. Miyaji Y, Saika T, Yamamoto Y, Kusaka N, Arata R, Ebara S, Nasu Y, Tsushima T, Kumon H. Effects of gonadotropin-releasing hormone agonists on bone metabolism markers and bone mineral density in patients with prostate cancer. Urology 2004; 64: 128-131
23. Moore E, Wisniewski A, Dobs A. Endocrine treatment of transsexual people: a review of treatment regimens, outcomes, and adverse effects. J Clin Endocrinol Metab 2003; 88: 3467-3473
24. Ongphiphadhanakul B, Rajatanavin R, Chanprasertyothin S, Piaseu N, Chailurkit L. Serum oestradiol and oestrogen-receptor gene polymorphism are associated with bone mineral density independently of serum testosterone in normal males. Clin Endocrinol 1998; 49: 803-809
25. Rosing J, Curvers J, Tans G. Oral contraceptives, thrombosis and haemostasis. Eur J Obstet Gynecol Reprod Biol 2001; 95: 193-197
26. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J, Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative Randomized Controlled Trial. J Am Med Assoc 2002; 288: 321-333
27. Schlatterer K, Auer DP, Yassouridis A, von Werder K, Stalla GK. Trans-sexualism and osteoporosis. Exp Clin Endocrinol Diabetes 1998; 106: 365-368
28. Slemenda CW, Longcope C, Zhou L, Hui SL, Peacock M, Johnston CC. Sex steroids and bone mass in older man: positive associations with serum estrogens and negative associations with androgens. J Clin Invest 1997; 100: 1755-1759
29. Smith MR. Management of treatment-related osteoporosis in men with prostate cancer. Cancer Treatment Reviews 2003; 29: 211-218
30. Smith MR, Fallon MA, Lee H, Finkelstein JS. Raloxifene to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer: a randomized controlled trial. J Clin Endocrinol Metab 2004; 89: 3841-3846
31. Stadel BV. Oral contraceptives and cardiovascular disease. New Engl J Med 1981; 305: 612-618, 672-677
32. Tans G, Bouma BN, Buller HR, Rosing J. Changes of hemostatic variables during oral contraceptive use. Sem Vascular Med 2003; 3: 61-68
33. Toorians AW, Thomassen MC, Zweegman S, Magdeleyns EJ, Tans G, Gooren LJ, Rosing J. Venous thrombosis and changes of hemostatic variables during cross-sex hormone treatment in transsexual people. J Clin Endocrinol Metab 2003; 88: 5723-5729
34. Townsend MF, Sanders WH, Northway RO, Graham SD Jr. Bone fractures associated with luteinizing hormone-releasing hormone agonists used in the treatment of prostate carcinoma. Cancer 1997; 79: 545-550
35. Van Kesteren P. Recent advances in gender dysphoria. Paper presented at a conference of the Royal Society of Medicine Sexual Health and Reproductive Medicine Section 2002; London: 16 April 2002
36. Van Kesteren P, Lips P, Deville W, Popp-Snijders C, Asscheman H, Megens J, Gooren L. The effect of one-year cross-sex hormonal treatment on bone metabolism and serum insulin-like growth factor-1 in trans-sexuals. J Clin Endocrinol Metab 1996; 81: 2227-2232
37. Van Kesteren P, Asscheman H, Megens J, Gooren L. Mortality and morbidity in transsexual subjects treated with cross-sex hormones. Clin Endocrinol (Oxford) 1997; 47: 337-342
38. Van Kesteren P, Lips P, Gooren LJ, Asscheman H, Megens J. Long-term follow-up of bone mineral density and bone metabolism in transsexuals treated with cross-sex hormones. Clin Endocrinol (Oxford) 1998; 48: 347-354
39. Vermeulen A, Verdonck L, Kaufmann JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab 1999; 84: 3666-3672
40. Vermeulen A, Kaufman JM, Goemaere S, van Pottelberg I. Estradiol in elderly men. Aging Male 2002; 5: 98-102
41. Ylostalo P, Laakso L, Viinikka L, Ylikorkala O, Vihko R. Cyproterone acetate in the treatment of hirsutism. Acta Obstetricia Gynecologica Scandinavica 1981; 60: 399-401